KOSDAQ - Delayed Quote KRW

Hyundai Bioscience Co., Ltd. (048410.KQ)

11,300.00

+790.00

+(7.52%)

At close: 3:30:15 PM GMT+9

Penetrium™ Breaks Oncology Barriers: The Solution to Cold Tumors and Metastatic Cancer Unveiled at AACR 2025

Hyundai Bioscience presented the results of its Penetrium™ combination preclinical studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting, held in Chicago.

PR Newswire 14 days ago

048410.KQ
+7.52%

048410.KS
Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience's Xafty by UCSD

Hyundai Bioscience USA announced that it has signed an MOU with the University of California San Diego (UCSD) to conduct an investigator-initiated trial to evaluate the efficacy of Xafty®, a niclosamide-based antiviral developed by its Korean headquarters, in treating "Long-COVID". The trial will be led by UCSD Professor Ajay Bharti, an infectious disease specialist and clinical trialist. Dr. Bharti's particular expertise in the neurocognitive effects of viral illnesses make him perfectly suited

PR Newswire 7 months ago

048410.KQ
+7.52%

048410.KS
Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue

Dr. Heung-Jeong Woo, a vice president of Hyundai Bioscience shared insights on the current state of antiviral treatments at the "Disease Prevention and Control Summit 2024." He highlighted the lack of effective therapies for global public health threats like COVID-19, dengue, mpox, HIV/AIDS, and influenza type A (H1N1), and expressed confidence in XAFTY®'s potential to treat all of these.

PR Newswire 8 months ago

048410.KQ
+7.52%

048410.KS
Hyundai Bioscience to conduct phase 3 clinical trial for high-risk group of COVID-19 patients with the goal of emergency use authorization

Hyundai Bioscience Co., Ltd, currently pursuing Emergency Use Authorization (EUA) for its oral COVID-19 treatment, Xafty®, for mild-to-moderate cases, announced on August 27th that it has submitted an Investigational New Drug (IND) application for Phase 3 clinical trial to the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea. This new trial will specifically target high-risk group patients with mild-to-moderate COVID-19.

PR Newswire 8 months ago

048410.KQ
+7.52%

048410.KS
ADM Korea Announces Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target as 'Prostate Cancer Patients Resistant to Hormone Therapy'

ADM Korea, a subsidiary of Hyundai Bioscience, announced on the 8th that the first clinical trial target population for its niclosamide-based oral metabolic anticancer drug will be 'prostate cancer patients resistant to hormone therapy.'

PR Newswire 10 months ago

048410.KQ
+7.52%

048410.KS
Hyundai Bioscience succeeds in developing 'Multi-treatment for mosquito-borne viral infections' including Dengue Fever

Hyundai Bioscience (CEO Oh Sang-gi), which is preparing for a dengue fever basket clinical trial in Brazil, announced on the 24th that it has successfully developed a 'multi-treatment drug for mosquito-borne viral infections, including dengue fever,' using niclosamide as the main ingredient. This treatment, which contains niclosamide as the main active pharmaceutical ingredient, can maintain a blood niclosamide concentration (IC50) to inhibit the proliferation of viruses such as the four serotyp

PR Newswire 10 months ago

048410.KQ
+7.52%

048410.KS

Performance Overview

Return	048410.KQ	KOSPI Composite Index (^KS11)
YTD	-19.91%	+8.09%
1-Year	-43.92%	-4.77%
3-Year	-62.71%	-1.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Hyundai Bioscience Co., Ltd. (048410.KQ)

Penetrium™ Breaks Oncology Barriers: The Solution to Cold Tumors and Metastatic Cancer Unveiled at AACR 2025

Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience's Xafty by UCSD

Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue

Hyundai Bioscience to conduct phase 3 clinical trial for high-risk group of COVID-19 patients with the goal of emergency use authorization

ADM Korea Announces Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target as 'Prostate Cancer Patients Resistant to Hormone Therapy'

Hyundai Bioscience succeeds in developing 'Multi-treatment for mosquito-borne viral infections' including Dengue Fever

Performance Overview